Comparison · NCT01298999-33f06854
YF476 vs Placebo: Number of Participants That Experienced Change in Any Biomarker Expression
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. YF476 vs Placebo: Number of Participants That Experienced Change in Any Biomarker Expression. Trial comparisons, record NCT01298999-33f06854. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01298999-33f06854
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 1 | 0.722 | 1 | wilson | |
| Risk in group 2 | 0.9 | 0.596 | 0.982 | wilson | |
| Risk difference, group 1 minus group 2 | 0.1 | -0.189 | 0.404 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.11 | 0.904 | 1.37 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one more participant with the outcome on YF476 than on Placebo | 10 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | YF476 | YF476 (gastrin-receptor antagonist)~YF476: 25 mg: one capsule to be taken by mouth once daily for 12 weeks. | 10 | 10 | OG000 |
| Group 2 | Placebo | Placebo pill (identical in appearance to YF476 pills)~Placebo: Matching placebo: one capsule to be taken by mouth once daily for 12 weeks. | 9 | 10 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants That Experienced Change in Any Biomarker Expression
- Description
- Participants with changes in gene expression were assessed by RNA-sequencing (i.e., sample has sufficient RNA for analysis) between baseline and up to 3 months are tallied.
- Time frame
- Up to 3 months from baseline
- Population
- Analysis limited to those who completed study (10 subjects in the intervention group and 10 subjects in the placebo group).
Source ClinicalTrials.gov
Trial
- Title
- Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus
- NCT number
- NCT01298999
- Phases
- PHASE2
- Conditions
- Barrett's Esophagus
- Interventions
- YF476, Placebo
- Lead sponsor
- Columbia University
- Results first posted
- 2021-11-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01298999?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01298999-33f06854